Talins are adaptor proteins that connect the integrin family of cell adhesion receptors to cytoskeletal actin. Vertebrates express two closely related talins encoded by separate genes, and while it is well established that talin1 plays a key role in cell adhesion and spreading, little is known about the role of talin2. To facilitate such studies, we report the characterisation of 4 new isoform-specific talin mouse monoclonal antibodies that work in Western blotting, immuno-precipitation, immuno-fluorescence and immuno-histochemistry. Using these antibodies, we show that talin1 and talin2 do not form heterodimers, and that they are differentially localised within the cell. Talin1 was concentrated in peripheral focal adhesions while talin2 was observed in both focal and fibrillar adhesions, and knock-down of talin2 compromised fibronectin fibrillogenesis. Although differentiated human macrophages express both isoforms, only talin1 showed discrete staining and was localised to the ring structure of podosomes. However, siRNA-mediated knock-down of macrophage talin2 led to a significant reduction in podosomal matrix degradation. We have also used the antibodies to localise each isoform in tissue sections using both cryostat and paraffin-embedded material. In skeletal muscle talin2 was localised to both myotendinous junctions and costameres while talin1 was restricted to the former structure. In contrast, both isoforms co-localised in kidney with staining of the glomerulus, and the tubular epithelial and interstitial cells of the cortex and medulla. We anticipate that these antibodies will form a valuable resource for future studies on the function of the two major talin isoforms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629562 | PMC |
http://dx.doi.org/10.1016/j.ejcb.2011.12.003 | DOI Listing |
Eur J Cancer Prev
January 2025
Department of Dermatology, University of Pisa.
Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer.
View Article and Find Full Text PDFBackground: This study aims at applying the AT(N) classification to a cohort of patients with Alzheimer's disease (AD) and related disorders, and to investigate how many cases would be eligible for the emerging disease-modifying treatments.
Method: We conducted a retrospective evaluation of 429 patients referred to the Memory Center of IRCCS San Raffaele Hospital in Milan. Patients underwent clinical/neuropsychological assessments, lumbar puncture, structural brain imaging, and positron emission tomography (FDG-PET).
Background: Alzheimer's disease (AD) is the most common cause of a decline in cognitive ability. The pathogenesis of AD involves the deposition of β-amyloid (Aβ) plaques and the formation of neurotoxic oligomers of Aβ protein. This leads to neurofibrillary tangles composed of phosphorylated Tau proteins, neuroinflammation, loss of nerve cells and synapses, and ultimately dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurocognitive Unit, Division of Neurology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Alzheimer's disease(AD) raises global concern with its impact on daily living. Anti-amyloid monoclonal antibodies (mAb) serving as specific treatments used in mild cognitive impairment(MCI) and mild dementia due to AD. Severe cerebral small vessel disease(SVD) lesions such as microbleeds and white matter hyperintensities are listed as exclusions according to the recommendation for mAb treatment.
View Article and Find Full Text PDFBackground: Lecanemab, an anti-amyloid therapy for early Alzheimer's disease (AD), received full FDA approval in July 2023 and subsequent approval in Japan in September 2023. Public reaction on social media was mixed, reflecting opinions on its efficacy, safety, and cost. We aimed to evaluate public perception of lecanemab's approval on social media, aiming to inform future communications and development strategies for anti-amyloid treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!